7347 The Efficacy And Safety Of Oral Semaglutide In Asian Patients With Type 2 Diabetes:A Systematic Review And Meta-Analysis
Year: 2024
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: Disclosure: T. Wang: None. L. Liao: None. Objectives: To evaluate the efficacy and safety outcomes of oral semaglutide in Asian and non-Asian patients with type 2 diabetes mellitus(T2DM). Methods: Search several databases for randomized controlled trials (RCTs) of oral semaglutide in patients with T2DM. The primary outcomes included Participants who achieved HbA1c <7.0% (53 millimoles per mole [mmol/mol]), Participants losing 5% or more of baseline body weight, adverse events (AE), serious adverse events (SAE). Risk ratios (RR) and 95% confidence intervals (CI) were calculated to evaluate the outcomes. Results: This meta-analysis included 8 RCTs with a total of 5662 patients. Using a placebo as a control group, semaglutide was effective in controlling blood sugar and reducing body weight in both Asian and non-Asian subgroups. meanwhile, compared to non-Asians, semaglutide 3mg(Chi2 4.54, P=0.03, I2=78%, 2 subgroup), 7mg (Chi2 7.79, P=0.005, I2=87.2%, 2 subgroup), 14mg (Chi2 7.97, P=0.005, I2=87.4%, 2 subgroup) oral preparation can make the level of HBA1c in Asian race more reach the therapeutic target. In Asian or non-Asian subgroups, semaglutide significantly reduced patient weight compared to active medicine. And semaglutide did not increase the risk of adverse reactions, whether Asian or not. Conclusion: Oral semaglutide is more effective in Asians, and semaglutide 7mg or 14mg is preferred over other active medicines. Presentation: 6/3/2024
Source: Journal of the Endocrine Society
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,418
OpenAlex ID: W4403148856